EcoDrugPlus

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSLOCG00000011998
Gene Symbol: LOC102693230
3 Cross references
262 Possible Orthologues:

C-X-C Motif Chemokine Receptor 1

Ensembl ID : ENSLOCG00000017836
Gene Symbol: CXCR1
3 Cross references
275 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSLOCG00000000937
Gene Symbol: CXCR4
3 Cross references
280 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSLOCG00000015585
Gene Symbol: CFTR
1 Cross references
216 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSLOCG00000007421
Gene Symbol: DNMT1
3 Cross references
210 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSLOCG00000004545
Gene Symbol: TOP1
3 Cross references
266 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSLOCG00000012897
Gene Symbol: TOP2A
3 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSLOCG00000006909
Gene Symbol: TOP2B
3 Cross references
208 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSLOCG00000016471
Gene Symbol: EML4
4 Cross references
212 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSLOCG00000010477
Gene Symbol: EPHA3
3 Cross references
215 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSLOCG00000011493
Gene Symbol: F2RL3
3 Cross references
195 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSLOCG00000016987
Gene Symbol: FYN
3 Cross references
259 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).